NEW YORK, March 19, 2014 /PRNewswire/ -- Anterios, Inc., a privately held aesthetic medicine and medical dermatology biopharmaceutical company, announced today development of a next generation injectable botulinum product, AI-09. Unlike currently commercialized injectable botulinum products that all require reconstitution from a powdered form prior to injection, AI-09 will be packaged as a ready-to-use injectable liquid. AI-09 is a complementary product to the company's topical botulinum prescription Phase IIb product ANT-1207, which is being developed for wrinkles, hyperhidrosis (excessive sweating), and acne and has been studied in US clinical trials involving over 500 subjects to date. Both products utilize Anterios' breakthrough delivery technology which, when applied to injectable formulations, addresses several of the current issues with injectable botulinum products.
"We're pleased to leverage our proprietary delivery technology platform to develop a new product that is complementary to ANT-1207," stated Jon Edelson, MD, CEO and Founder of Anterios. "Alongside ANT-1207, AI-09 will enable us to offer the complete breadth of next-generation botulinum-based treatment modalities that physicians are seeking for the benefit of their patients. We believe the platform has the potential to enable the development of many other proprietary biologic and small molecule products."
Currently, all injectable botulinum products on the market are lyophilized (freeze-dried), contain albumin, and must be reconstituted in the physician's office prior to use. AI-09 utilizes neither lyophilization nor albumin, and will be packaged as a ready-to-use injectable liquid in bottles or pre-filled syringes. These enhancements reduce manufacturing costs, produce a safer product for patients and offer a more convenient product for physicians. AI-09 has demonstrated therapeutic equivalence to the current generation of reconstituted commercialized products in a standard pre-clinical model as well as excellent long-term stability.
"The potential for AI-09 is exciting for the dermatology community, as there is always a need to continue to innovate and improve upon the products we currently offer to our patients," states Timothy C. Flynn, MD, independent clinical investigator working with Anterios since 2007, dermatologist in private practice, the immediate past President of the American Society of Dermatologic Surgery, and Clinical Professor of Dermatology at the University of North Carolina at Chapel Hill. "Offering an equally effective but more convenient injectable botulinum toxin product would be an advance in the field."
Anterios, Inc. and their products in development will be discussed in Dr. Flynn's presentation titled "Differentiating Botulinum Toxin Type A Preparations: Basic and Clinical Science" at the annual meeting of The American Academy of Dermatology in Denver on March 24th.
ANT-1207, Botulinum Toxin Type A, Topical Lotion, is an investigational product being developed for the potential treatment of facial wrinkles, hyperhidrosis (excessive sweating) and other FDA-approved clinical indications for injectable botulinum as well as new potential clinical indications such as acne. The Company believes that this treatment has the potential to greatly expand the market for botulinum as it would overcome the limitations of injection, which include pain, bleeding and bruising as well as the potential for needle misplacement.
ANT-1207 is a lotion that takes five to ten minutes to apply in the physician's office using just a gloved finger. Unlike many botulinum-based products, ANT-1207 does not require reconstitution in the physician's office prior to use, making it convenient and time-saving for the physician and the physician's staff. ANT-1207 incorporates a highly purified botulinum developed from Anterios' proprietary cell line of C. Botulinum Type A.
About Anterios, Inc.
Anterios, Inc. ("Anterios") is a privately held clinical stage biopharmaceutical company which is developing next generation botulinum-based prescription products for aesthetic medicine and dermatology. Anterios has developed a proprietary platform technology that enables local, targeted delivery of botulinum toxin and other macromolecules across the skin without needles or other invasive treatments that can be destructive to the skin. In the future, Anterios plans to develop additional dermatology products to topically deliver other active ingredients, as well as products for delivery by other modalities. More information can be found at www.anteriosinc.com
SOURCE Anterios, Inc.